1-8 of 8
Rafael Rios Tamayo
Close
Sort by
Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Clinical Trials & Observations Brief Report
Camila Guerrero, Noemi Puig, María-Teresa Cedena, María-José Calasanz, Norma C. Gutierrez, Manuela Fernandez, Albert Oriol, Rafael Ríos-Tamayo, Miguel-Teodoro Hernandez, Rafael Martínez-Martínez, Joan Bargay, Felipe de Arriba, Luis Palomera, Ana Pilar Gonzalez-Rodriguez, Marta-Sonia Gonzalez Perez, Alberto Orfao, María-Victoria Mateos, Joaquin Martinez-Lopez, Laura Rosiñol, Joan Bladé, Juan-Jose Lahuerta, Jesus F. San-Miguel, Bruno Paiva
Journal: Blood
Blood (2024) 143 (7): 597–603.
https://doi.org/10.1182/blood.2023022083
Published: 2024
Includes: Supplemental data
Journal Articles

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Laura Rosinol, Albert Oriol, Rafael Ríos Tamayo, María Jesús Blanchard, Isidro Jarque, Joan Bargay, Miguel-Teodoro Hernández, Jose Maria Moraleda, Estrella Carrillo-Cruz, Anna Sureda, Joaquín Martínez-López, Isabel Krsnik, Esther González Garcia, Felipe Casado, Josep M Marti, Cristina Encinas, Felipe De Arriba, Luis Palomera, Antonia Sampol, Yolanda Gonzalez-Montes, Elena Cabezudo, Maria-Victoria Mateos, Jesus San-Miguel, Juan Jose Lahuerta, Joan Bladé Creixenti
Journal: Blood
Blood (2021) 138 (Supplement 1): 466.
https://doi.org/10.1182/blood-2021-146798
Published: 2021
Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos
Journal: Blood
Blood (2019) 134 (Supplement_1): 694.
https://doi.org/10.1182/blood-2019-123997
Published: 2019
Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Maria-Victoria Mateos, Joaquin Martinez-Lopez, MD PhD, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Marta Sonia Gonzalez, MD, Albert Oriol, MD, Norma C. Gutierrez, MD PhD, Bruno Paiva, PhD, Rafael Ríos Tamayo, Laura Rosinol Dachs, Miguel Angel Alvarez, MD, Maria Jose Calasanz, PhD BSc, Joan Bargay, MD PhD, Ana Pilar Gonzalez, PhD, Adrián Alegre Amor, MD, Fernando Escalante, MD, Belén Iñigo, Noemi Puig, MD PhD, Javier De La Rubia, Ana Isabel Teruel, MDcal Doctor, Maria Teresa Cedena Romero, MD PhD, Felipe De Arriba, PhD, Luis Palomera, MD PhD, Miguel T Hernández, Javier Lopez Jimenez, MD, Jesús Martín, Aránzazu García Mateo, PhD, Enrique M. Ocio, Joan Bladé, MD, Juan Jose Lahuerta, MD PhD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 781.
https://doi.org/10.1182/blood-2019-125204
Published: 2019
Journal Articles

Immunoglobulin Heavy/Light Chain Ratio and Suppression of the Myeloma Non-Involved Heavy/Light Chain Pair Isotype Correlate with Poor Survival in Multiple Myeloma at Diagnosis and after Autologous Stem Cell Transplant

José Luís García de Veas Silva, Nuno Barbosa, Rafael Rios Tamayo, Carmen Bermudo Guitarte, Tiago M Pais, PhD, Teresa Rodríguez Ruiz
Journal: Blood
Blood (2016) 128 (22): 5647.
https://doi.org/10.1182/blood.V128.22.5647.5647
Published: 2016
Journal Articles

Multiple Myeloma with Prior Precursor Disease Shows Better Outcome

Rafael Ríos-Tamayo, MD, Juan Sáinz Pérez, Manuel Jurado, MD, Jose Manuel Puerta Puerta, MD, Pedro Antonio González Sierra, MD, Antonio Romero Aguilar, MD, Elisa Lopez Fernandez, MD, Lucia Moratalla Lopez, MD, José Luís García de Veas Silva, Teresa Rodríguez Ruiz, José Juan Jiménez Moleón, MD, María José Sánchez Pérez, MD
Journal: Blood
Blood (2015) 126 (23): 1756.
https://doi.org/10.1182/blood.V126.23.1756.1756
Published: 2015
Journal Articles

The Role of PET/TC in the Full Range of Monoclonal Gammopathies

Rafael Ríos Tamayo, Juan Sáinz Pérez, Jose Manuel Puerta Puerta, Rosario Leyva Ferrer, Youssef Moatassim de la Torre, Pilar López Garrido, José María de Pablos Gallego, Alvaro Miguel Alba Sosa, Elisa Lopez Fernandez, Lucia Moratalla Lopez, Antonio Romero Aguilar, Manuel Jurado, MD, Jose Manuel Llamas Elvira, Antonio Rodriguez Fernandez, Rocio Sanchez Sanchez
Journal: Blood
Blood (2014) 124 (21): 3365.
https://doi.org/10.1182/blood.V124.21.3365.3365
Published: 2014
Journal Articles

Prognostic Impact Of Comorbidity In Multiple Myeloma

Rafael Ríos Tamayo, Joaquín Martínez López, Manuel Jurado, María Esther Clavero Sánchez, Fátima López Jiménez, María Liz Paciello Coronel, José Ramón García Fernández, Youssef Moatassim de la Torre, Francisco López Berenguel, Rosario Leyva Ferrer, Juan Sáinz Pérez, Elena Molina Portillo, María José Sánchez Pérez, José María de Pablos Gallego, Pilar López Garrido, José Juan Jiménez Moleón, Amaia López de Lacalle, Juan José Lahuerta Palacios
Journal: Blood
Blood (2013) 122 (21): 5340.
https://doi.org/10.1182/blood.V122.21.5340.5340
Published: 2013